Quetiapine fumarate-This medication is used to treat certain mental/mood conditions

This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type).

Quetiapine fumarate-This medication is used to treat certain mental/mood conditions

Quetiapine fumarate; Quetiapine hemifumarate; Seroquel XR; UNII-2S3PL1B6UJ

Adequet, Esq, Pincalm, Placidin, Psynil, Q Pin, Q-Mind, Q-Win, Qtf, Qtf-SR, Quel, Quel-SR, Queticare, Quetimax, Quitsun, Qurea, Quser, Quser-XL, Qutace, Qutace-SR, Qutan, Quticool, Quticool-SR, Qutipin, Qutipin-SR, Seroqui

2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,?]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol

• Absorption: Oral
• Distribution: 83% protein binding
• Metabolism: Hepatic
• Excretion: Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.

Quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT₂), and dopamine type 2 (D2) receptors. It is an antagonist at dopamine D1 and D2, serotonin 5-HT_1A and 5HT₂, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Initial dose is 25-50 mg twice a day, may increase dose 750-800 mg per day.

Used in the management of schizophrenia, bipolar I depression, bipolar I mania, bipolar II depression, insomnia and anxiety disorders.

Headache, asthenia, abdominal pain, back pain, fever, chest pain, postural and orthostatic hypotension, hypertension, constipation, dry mouth, dyspepsia, diarrhoea, leucopenia, elevations in serum transaminase level, weight gain, myalgia, somnolence, dizziness, anxiety, rhinitis, rash, dry skin, ear pain, UTI, syncope, neuroleptic malignant syndrome, variations in WBC count, neutropenia, eosinophilia, elevations in nonfasting serum triglyceride level and total cholesterol, decrease in thyroid hormone levels, prolongation of the QTc interval.

• Increased risk of drowsiness and postural hypotension when used with alcohol.
• CYP3A4 inhibitors eg. ketoconazole and erythromycin may increase its plasma levels.
• CYP3A4 inducers eg. carbamazepine and phenytoin may decrease plasma levels of quetiapine.

Severe CNS depression, bone marrow suppression, coma.

Store at 25°C.

Molecular weight

383.507

Molecular formula

C21H25N3O2S

CAS number

111974-72-2

Precautions

• Monitor patients for symptoms of hyperglycemia. 
• Advise families and caregivers of the need for close observation and communication with the prescriber.
• Monitor all patients for the emergence of irritability, agitation, and other unusual changes in behavior, as well as the emergence of suicidality, especially during the initial few months of therapy or at times of dose changes.
•  Quetiapine is not approved for use in children.
• Carefully monitor patients with neutropenia for fever or other symptoms or signs of infection.
• Hepatic or renal impairment.
• CV disease, cerebrovascular disease or conditions that predispose to hypotension. 
• Gradual withdrawal is recommended.
• History of seizures; neuroleptic malignant syndrome; tardive dyskinesia.